EGFR and esophageal squamous cell carcinoma: Cisplatin, RTKs inhibitors (sunitinib), EGFR inhibitors (erlotinib and gefitinib), HER-2 inhibitor (lapatinib), and multikinase inhibitor (sorafenib) were widely used and studied in the treatment of ESCC and EAC (Yang et al., 2020b).